|
Press Releases |
|
|
|
Tuesday, March 26, 2024 |
|
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine |
Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine. more info >> |
|
Monday, December 11, 2023 |
|
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event |
more info >> |
|
Moderna公司回顧了在第二次環境、社會和治理(ESG)投資者活動中取得的進展和雄心 |
more info >> |
|
Wednesday, July 5, 2023 |
|
Moderna Announces Global Regulatory Submissions for Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345 |
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older. more info >> |
|
Wednesday, May 3, 2023 |
|
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines |
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an Enterprise Solutions Hub in the Philippines. The Moderna Enterprise Solutions Hub will provide business services across the Asia Pacific region, where Moderna currently has operations in six markets. Moderna also plans to establish commercial operations in the Philippines. more info >> |
|
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines |
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an Enterprise Solutions Hub in the Philippines. The Moderna Enterprise Solutions Hub will provide business services across the Asia Pacific region, where Moderna currently has operations in six markets. Moderna also plans to establish commercial operations in the Philippines. more info >> |
|
Tuesday, September 13, 2022 |
|
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines |
PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in manufacturing IndoVac, a Covid-19 vaccine brand it has developed since November 2021. more info >> |
|
Friday, September 9, 2022 |
|
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines |
PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in the manufacturing process of IndoVac, a Covid-19 vaccine brand it has developed since November 2021. more info >> |
|
Tuesday, July 19, 2022 |
|
Therapeutic Goods Administration Grants Provisional Approval for Moderna's COVID-19 Vaccine in Children Aged Six Months to Five Years |
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 ug per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to 5 years. more info >> |
|
Thursday, February 17, 2022 |
|
Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years) |
Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a 50 ug dose, two-dose series, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6-11 years. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
|
|
|
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
|
|
|
三菱重工、タイの超大型複合火力発電所プロジェクトでM701JAC形GTCCの7系列目が運転開始
Apr 24, 2024 14:30: JST
|
|
|
トヨタ・モビリティ基金、「自転車事故削減に向けた新たな官民連携のあり方」に関するシンポジウムを開催
Apr 24, 2024 14:00: JST
|
|
|
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
|
|
|
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
|
|
|
一站式金融媒体发布平台「全球速发布」重磅推出!
Apr 24, 2024 10:52 HKT/SGT
|
|
|
一站式金融媒體發佈平台「全球速發佈」重磅推出!
Apr 24, 2024 10:35 HKT/SGT
|
|
|
Honda、新型SUV「WR-V」受注状況について
Apr 24, 2024 10:00: JST
|
|
|
三菱みなとみらい技術館に「空・宇宙ゾーン」を新設、リニューアルオープン
Apr 24, 2024 10:00: JST
|
|
|
Dogs Thrive on Vegan Diets, Demonstrates the Most Comprehensive Study So Far
Apr 24, 2024 07:00 HKT/SGT
|
|
|
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 23, 2024 23:06: JST
|
|
|
Graid Technology Announces Software Update, Delivers Enhanced Levels of Data Integrity and Business Continuity
Apr 23, 2024 23:00 HKT/SGT
|
|
|
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 23, 2024 22:00 HKT/SGT
|
|
|
GA-ASI Mojave Lights Up the Yuma Desert in Live-Fire Demonstration
Apr 23, 2024 20:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|